CENTRAL TRUST Co Lowers Position in Bristol Myers Squibb Company $BMY

CENTRAL TRUST Co cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,648 shares of the biopharmaceutical company’s stock after selling 9,285 shares during the period. CENTRAL TRUST Co’s holdings in Bristol Myers Squibb were worth $5,080,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares in the last quarter. Total Investment Management Inc. purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the second quarter worth $40,000. Finally, Mark Sheptoff Financial Planning LLC boosted its position in Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 1.3%

Bristol Myers Squibb stock opened at $60.64 on Friday. The firm has a 50 day simple moving average of $55.33 and a 200 day simple moving average of $49.44. The company has a current ratio of 1.26, a quick ratio of 1.17 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The firm has a market capitalization of $123.49 billion, a price-to-earnings ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the firm earned $1.67 EPS. The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMY. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Morgan Stanley restated an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Guggenheim reiterated a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.